These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 28398272)

  • 1. Prognostic and predictive biomarkers in metastatic castration-resistant prostate cancer.
    Armstrong AJ
    Clin Adv Hematol Oncol; 2017 Mar; 15(3):184-188. PubMed ID: 28398272
    [No Abstract]   [Full Text] [Related]  

  • 2. Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet.
    Petrylak DP; Crawford ED
    Target Oncol; 2017 Aug; 12(4):401-412. PubMed ID: 28620691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Biomarkers in metastatic castration-resistant prostate cancer].
    Miller K
    Aktuelle Urol; 2015 Jan; 46(1):66-70. PubMed ID: 25658233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment.
    Del Re M; Crucitta S; Restante G; Rofi E; Arrigoni E; Biasco E; Sbrana A; Coppi E; Galli L; Bracarda S; Santini D; Danesi R
    Crit Rev Oncol Hematol; 2018 May; 125():51-59. PubMed ID: 29650277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The time for molecular phenotyping of metastatic castrate-resistant prostate cancer is now.
    VanderWeele DJ
    Clin Adv Hematol Oncol; 2015 Sep; 13(9):580-3. PubMed ID: 26452188
    [No Abstract]   [Full Text] [Related]  

  • 6. Advances in systemic therapies for metastatic castration-resistant prostate cancer.
    Pant MK; Abughaban A; Aragon-Ching JB
    Future Oncol; 2014 Nov; 10(14):2213-26. PubMed ID: 25471035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers in castration-resistant prostate cancer.
    Armstrong AJ
    Clin Adv Hematol Oncol; 2014 Feb; 12(2):115-8. PubMed ID: 24892256
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic and Theranostic Applications of Positron Emission Tomography for a Personalized Approach to Metastatic Castration-Resistant Prostate Cancer.
    Filippi L; Frantellizzi V; Chiaravalloti A; Pontico M; De Feo MS; Corica F; Montebello M; Schillaci O; De Vincentis G; Bagni O
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer.
    Josefsson A; Linder A; Flondell Site D; Canesin G; Stiehm A; Anand A; Bjartell A; Damber JE; Welén K
    Prostate; 2017 Jun; 77(8):849-858. PubMed ID: 28295408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer.
    Conteduca V; Mosca A; Brighi N; de Giorgi U; Rescigno P
    Cells; 2021 Jan; 10(1):. PubMed ID: 33478015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer.
    Buonerba C; Di Lorenzo G; Sonpavde G
    Expert Rev Mol Diagn; 2016 Oct; 16(10):1113-1120. PubMed ID: 27665838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Insights into Long Non-Coding RNAs (LncRNAs) in Prostate Cancer.
    Smolle MA; Bauernhofer T; Pummer K; Calin GA; Pichler M
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28241429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ser-486/491 phosphorylation and inhibition of AMPKα activity is positively associated with Gleason score, metastasis, and castration-resistance in prostate cancer: A retrospective clinical study.
    Babcook MA; Akgul M; Margevicius S; MacLennan GT; Fu P; Abouassaly R; Gupta S
    Prostate; 2018 Jul; 78(10):714-723. PubMed ID: 29577356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Navigating the evolving therapeutic landscape in advanced prostate cancer.
    Crawford ED; Petrylak D; Sartor O
    Urol Oncol; 2017 May; 35S():S1-S13. PubMed ID: 28283376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers in prostate cancer - Current clinical utility and future perspectives.
    Kretschmer A; Tilki D
    Crit Rev Oncol Hematol; 2017 Dec; 120():180-193. PubMed ID: 29198331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Metastatic castration resistant prostate cancer: 2018 perspective.].
    Miñana López B
    Arch Esp Urol; 2018 Sep; 71(8):625-627. PubMed ID: 30319122
    [No Abstract]   [Full Text] [Related]  

  • 17. Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer.
    Aziz A; Kempkensteffen C; May M; Lebentrau S; Burger M; Chun FK; Brookman-May S
    Expert Rev Anticancer Ther; 2015 Jun; 15(6):649-66. PubMed ID: 25905802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stromal factors involved in human prostate cancer development, progression and castration resistance.
    Eiro N; Fernandez-Gomez J; Sacristán R; Fernandez-Garcia B; Lobo B; Gonzalez-Suarez J; Quintas A; Escaf S; Vizoso FJ
    J Cancer Res Clin Oncol; 2017 Feb; 143(2):351-359. PubMed ID: 27787597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.
    Bitting RL; Healy P; Halabi S; George DJ; Goodin M; Armstrong AJ
    Urol Oncol; 2015 Mar; 33(3):110.e1-9. PubMed ID: 25595577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TCTP Has a Crucial Role in the Different Stages of Prostate Cancer Malignant Progression.
    Baylot V; Karaki S; Rocchi P
    Results Probl Cell Differ; 2017; 64():255-261. PubMed ID: 29149413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.